Clementia Pharmaceuticals
Ipsen is a global biopharmaceutical company dedicated to improving patients' lives through research and innovation in oncology, rare disease, and neuroscience. With a focus on high unmet medical needs, Ipsen accelerates its pipeline and leverages its resources, expertise, and global presence to develop new therapies and collaborations. The company emphasizes sustainability, patient-centricity, and a culture of collaboration and excellence, aiming to be a leading global mid-size biopharmaceutical firm.
Industries
Nr. of Employees
Very Large (1000+)
Clementia Pharmaceuticals
Patents
Products
Bylvay (odevixibat)
Prescription pharmaceutical product; active ingredient listed as odevixibat.
Cabometyx (cabozantinib)
Prescription pharmaceutical product; active ingredient listed as cabozantinib.
Diphereline (triptorelin embonate)
Prescription pharmaceutical product; active ingredient listed as triptorelin embonate.
Dysport (clostridium botulinum type A toxin-haemagglutinin complex)
Neurotoxin therapeutic product; active ingredient described as clostridium botulinum type A toxin‑haemagglutinin complex.
Iqirvo (elafibranor)
Prescription pharmaceutical product; active ingredient listed as elafibranor.
Increlex (mecasermin)
Prescription pharmaceutical product; active ingredient listed as mecasermin.
Bylvay (odevixibat)
Prescription pharmaceutical product; active ingredient listed as odevixibat.
Cabometyx (cabozantinib)
Prescription pharmaceutical product; active ingredient listed as cabozantinib.
Diphereline (triptorelin embonate)
Prescription pharmaceutical product; active ingredient listed as triptorelin embonate.
Dysport (clostridium botulinum type A toxin-haemagglutinin complex)
Neurotoxin therapeutic product; active ingredient described as clostridium botulinum type A toxin‑haemagglutinin complex.
Iqirvo (elafibranor)
Prescription pharmaceutical product; active ingredient listed as elafibranor.
Increlex (mecasermin)
Prescription pharmaceutical product; active ingredient listed as mecasermin.
Services
Sponsorship and operational support for interventional and observational clinical studies across phases I–IV, using a global network of investigators.
Collaborative partnerships with biotech and academic partners to source, co-develop and license early-stage and later-stage assets.
Medical information provision for products and local adverse event reporting channels for healthcare professionals and patients.
Sponsorship and operational support for interventional and observational clinical studies across phases I–IV, using a global network of investigators.
Collaborative partnerships with biotech and academic partners to source, co-develop and license early-stage and later-stage assets.
Medical information provision for products and local adverse event reporting channels for healthcare professionals and patients.
Expertise Areas
- Clinical trial management
- Drug development (molecule-to-medicine end-to-end)
- Oncology development
- Rare disease therapeutics
Key Technologies
- Clinical trials (Phases I–IV)
- Companion diagnostics and biomarker assays
- Digital health platforms and data analytics
- Neurotoxin therapeutic development
News & Updates
Ipsen reports strong growth across all therapeutic areas for the first half of 2025, reflecting the strength of its strategy and dedication of its teams.
Regulatory approval for a key cancer treatment in Europe.
Leadership updates at Ipsen.
New data on a rare disease treatment showing promising results.
Upcoming presentation at a major liver disease conference.
Promising results for a rare liver disease treatment.
Ipsen reports strong growth across all therapeutic areas for the first half of 2025, reflecting the strength of its strategy and dedication of its teams.
Regulatory approval for a key cancer treatment in Europe.
Leadership updates at Ipsen.
New data on a rare disease treatment showing promising results.
Upcoming presentation at a major liver disease conference.
Promising results for a rare liver disease treatment.